Mushonga mutsva weAntidiabetic une Triple Combination Therapy

Daewoong Pharmaceutical yakazivisa iwo epamusoro mhedzisiro yechikamu che3 chekiriniki yekuyedza kusanganisa katatu kweEnavogliflozin, mushonga mutsva weantidiabetic une meshini yeSGLT-2 inhibitor, ine Metformin uye Gemigliptin. Enavogliflozin ndeye SGLT-2 inhibitor yechirwere cheshuga mukuvandudzwa naDaewoong kekutanga muSouth Korea.               

Muzvinafundo Sungrae Kim weCatholic University of Korea Bucheon St. Mary's Hospital semuongorori anoronga uye vaongorori vakuru kubva kumasangano makumi maviri nevanomwe vakapinda muchikamu chechitatu chekuyedza kweEnavogliflozin semusanganiswa katatu neMetformin neGemigliptin. Chidzidzo chacho chakaitwa se-multi-center, randomized, double-mapofu, uye inoshanda-inodzorwa inosimbisa chikamu chechitatu chekliniki yekuedza iyo inosanganisira 27 varwere vane chirwere cheshuga chechipiri.

Varwere vane chirwere cheshuga cherudzi rwechipiri, vakapihwa Metformin neGemigliptin, vakapihwazve Enavogliflozin kana Dapagliflozin kwemavhiki makumi maviri nemana, uye shanduko yekutanga yeglycated hemoglobin (HbA2c) pakati pemapoka maviri ezvidzidzo yakaenzaniswa panguva yekurapa. Nekuda kweizvozvo, varwere vakapihwa Enavogliflozin vakaratidza kuderera kweHbA24c ne1% uye ne1% mune avo vakapihwa Dapagliflozin, zvichiratidza kusaderera kweEnavogliflozin kana ichienzaniswa neDapagliflozin.

Kuchengeteka kweEnavogliflozin kwakaongororwawo muvarwere vane chirwere cheshuga chiri pakati nepakati, avo vaida kurapwa kwakasanganiswa kweMetformin neGemigliptin, sezvo pakanga pasina kusatarisirwa kwakashata kwakashata kwezvinodhaka kana kusangana kwezvinodhaka. Kuchengetedzeka kweEnavogliflozin kwakaratidzwa kuburikidza neatatu akatevedzana ekiriniki miedzo ye monotherapy, metformin musanganiswa, uye Metformin uye Gemigliptin musanganiswa.

Muongorori anorongana, Muzvinafundo Kim akati, "Kuyedzwa kwekiriniki kweEnavogliflozin's katatu musanganiswa kurapa mukuenzanisa neDapagliflozin kune vangangoita mazana maviri nemakumi manomwe evarwere veKorea T270DM kwemavhiki makumi maviri nemana kwakaratidza kuchengetedzeka uye kunoshamisa kudzikisa shuga muropa kweEnavogliflozin." "Zvinotarisirwa kuti Enavogliflozin inova nzira yekurapa iri nani ine chiratidzo chemonotherapy uye musanganiswa kurapa," akawedzera.

Ichiburitsa mhedzisiro inonzwisisika kubva muchikamu chechitatu chekiriniki yekuedza yeEnavogliflozin katatu musanganiswa kurapa, Daewoong yave nhanho yekuswedera pakuburitswa kweSGLT-3 inhibitor kekutanga muSouth Korea. Daewoong anoronga kukurumidza kunyorera kubvumidzwa kwemushonga mutsva uye kutanga kwete chete Enavogliflozin asiwo Enavogliflozin/Metformin yakatarwa-dose-musanganiswa mushonga panosvika hafu yekutanga ya2. musanganiswa therapy ino Ndira.